Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Immunitybio Inc (IBRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: IBRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -84.42% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.53B USD | Price to earnings Ratio - | 1Y Target Price 11.25 |
Price to earnings Ratio - | 1Y Target Price 11.25 | ||
Volume (30-day avg) 6410451 | Beta -0.18 | 52 Weeks Range 2.28 - 10.53 | Updated Date 04/2/2025 |
52 Weeks Range 2.28 - 10.53 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.62 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-17 | When After Market | Estimate -0.13 | Actual -0.08 |
Profitability
Profit Margin - | Operating Margin (TTM) -918.98% |
Management Effectiveness
Return on Assets (TTM) -48.48% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2880545725 | Price to Sales(TTM) 171.33 |
Enterprise Value 2880545725 | Price to Sales(TTM) 171.33 | ||
Enterprise Value to Revenue 195.36 | Enterprise Value to EBITDA -8.99 | Shares Outstanding 853441984 | Shares Floating 204851716 |
Shares Outstanding 853441984 | Shares Floating 204851716 | ||
Percent Insiders 62.9 | Percent Institutions 9.88 |
Analyst Ratings
Rating 4.5 | Target Price 12.19 | Buy - | Strong Buy 3 |
Buy - | Strong Buy 3 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Immunitybio Inc
Company Overview
History and Background
ImmunityBio, Inc. (formerly NantKwest, Inc.) was founded in 2002. It is a late-clinical-stage immunotherapy company developing next-generation therapies to modulate the immune system to treat diseases, including cancer and infectious diseases.
Core Business Areas
- Oncology: Development and commercialization of immunotherapies for various cancers, including bladder cancer, pancreatic cancer and others. Focus on utilizing their cell-based therapies, antibody cytokine fusion proteins, and adenovirus vaccines.
- Infectious Diseases: Development of immunotherapies targeting infectious diseases, notably HIV. This includes research and clinical trials for vaccines and therapies.
Leadership and Structure
Dr. Patrick Soon-Shiong serves as the Executive Chairman and Global Chief Scientific and Medical Officer. The organizational structure involves research and development, clinical operations, manufacturing, and commercialization teams.
Top Products and Market Share
Key Offerings
- Anktiva (N-803, formerly ALT-803): An IL-15 superagonist complexed with an IL-15 receptor alpha chain Fc fusion protein. It is ImmunityBio's lead drug candidate and is being studied in bladder cancer, non-small cell lung cancer, and other cancers. Anktiva has been approved by the FDA in combination with BCG for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Competitors include Merck's Keytruda and other bladder cancer treatments.
- PD-L1 t-haNK: A natural killer cell therapy engineered to target PD-L1 expressing tumors. Currently in clinical trials for solid tumors. Competitors include other cell-based immunotherapy companies like Kite Pharma and Novartis, as well as checkpoint inhibitors from companies like Bristol Myers Squibb and Roche.
Market Dynamics
Industry Overview
The immunotherapy market is experiencing significant growth, driven by advances in cancer research and the development of novel therapies. This market is highly competitive and innovation-driven.
Positioning
Immunitybio Inc is positioned as an innovator in the immunotherapy space, with a focus on cell-based therapies and cytokine-based approaches. Their competitive advantage lies in their novel technology platforms and clinical trial results. However, they need to get their products to market quicker than competitors.
Total Addressable Market (TAM)
The global immunotherapy market is projected to reach hundreds of billions of dollars. ImmunityBio is targeting specific segments within this market, such as bladder cancer, and other cancers, and infectious diseases.
Upturn SWOT Analysis
Strengths
- Novel immunotherapy platforms
- Strong intellectual property portfolio
- Experienced leadership team
- FDA Approval for Anktiva
Weaknesses
- History of losses, funding reliant on chairman
- Dependence on key personnel
- Regulatory hurdles and clinical trial risks
- Complex manufacturing processes
Opportunities
- Expanding clinical applications of Anktiva
- Partnerships and collaborations with other companies
- Advancements in immunotherapy technologies
- Growth in the immunotherapy market
Threats
- Competition from established pharmaceutical companies
- Regulatory changes and challenges
- Clinical trial failures
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
- JNJ
Competitive Landscape
Immunitybio competes with large pharmaceutical companies in the oncology and infectious disease markets. Its advantage lies in its novel technology, but faces challenges in commercialization and market access compared to larger players.
Major Acquisitions
NantCell
- Year: 2016
- Acquisition Price (USD millions): 100
- Strategic Rationale: Acquired NantCell to bolster its cell therapy capabilities and expand its oncology pipeline.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by preclinical and clinical development milestones.
Future Projections: Future growth is dependent on the successful commercialization of Anktiva and other pipeline products. Analyst estimates vary widely based on clinical trial outcomes and market penetration.
Recent Initiatives: Recent initiatives include FDA submission and approval for Anktiva, expanding clinical trials for other indications, and partnerships to develop and commercialize products.
Summary
ImmunityBio is an innovative immunotherapy company with promising technologies and a recent FDA approval for Anktiva. However, it faces significant financial challenges, high operating losses and strong competition. Its success hinges on the successful commercialization of its products and continued clinical trial progress. The company's long-term prospects remain highly uncertain, necessitating careful risk assessment. Recent FDA approval has improved their position somewhat.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
MRK
Merck & Company Inc
MRK
Merck & Company Inc
PFE
Pfizer Inc
PFE
Pfizer Inc
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst estimates
- FDA Website
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary. This analysis is based on publicly available information and current understanding of the company and its market. The AI-based rating is based on a generalized assessment and is not a substitute for professional financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immunitybio Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2015-07-28 | President, CEO & Director Mr. Richard Gerald Adcock | ||
Sector Healthcare | Industry Biotechnology | Full time employees 680 | Website https://immunitybio.com |
Full time employees 680 | Website https://immunitybio.com | ||
ImmunityBio, Inc., a vertically-integrated commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include cytokine fusion proteins, vaccine vectors, and cell therapies. The company's platforms have generated nine first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. The company is based in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.